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Previously, we reported that treatment with the G9a histone methyltransferase inhibitor BIX01294 causes bone marrow
mesenchymal stem cells (MSCs) to exhibit a cardiocompetent phenotype, as indicated by the induction of the precardiac
markers Mesp1 and brachyury. Here, we report that combining the histone deacetylase inhibitor trichostatin A (TSA) with
BIX01294 synergistically enhances MSC cardiogenesis. Although TSA by itself had no eﬀect on cardiac gene expression,
coaddition of TSA to MSC cultures enhanced BIX01294-induced levels of Mesp1 and brachyury expression 5.6- and 7.2-fold.
Moreover, MSCs exposed to the cardiogenic stimulus Wnt11 generated 2.6- to 5.6-fold higher levels of the cardiomyocyte
markers GATA4, Nkx2.5, and myocardin when pretreated with TSA in addition to BIX01294. MSC cultures also showed a
corresponding increase in the prevalence of sarcomeric protein-positive cells when treated with these small molecule inhibitors.
These results correlated with data showing synergism between (1) TSA and BIX01294 in promoting acetylation of lysine 27 on
histone H3 and (2) BIX01294 and Wnt11 in decreasing β-catenin accumulation in MSCs. The implications of these ﬁndings are
discussed in light of observations in the early embryo on the importance of β-catenin signaling and histone modiﬁcations for
cardiomyocyte diﬀerentiation and heart development.

1. Introduction
The prevalence of cardiovascular diseases, and their impact
on human health, has spurred considerable research eﬀorts
into discovering new therapies. Many potential therapeutic
avenues have been explored including novel surgical interventions, genetic manipulations, cytokine injections, and cell
transplantations. Great hope was placed on stem cell-based
treatments, which have yet to deliver on their initial promise
as a panacea for cardiac disease. However, cardiac-competent
stem cells are still the focus of therapeutic research, as scientists continue to investigate the capabilities of stem cells to
heal the heart either by their introduction into native tissue
as nondiﬀerentiated cells or as a source of cells that can be

used for generating diﬀerentiated myocytes within bioengineered tissue [1–5].
Bone marrow has long been studied as a potential
resource for treating the heart due to its accessibility and
abundance of stem cells [6–11]. However, initial enthusiasm
for using bone marrow to heal the heart has been tempered
with disappointment, as stem cells from this noncardiac
tissue have not shown a suﬃcient native potential to generate
myocardial tissue [9, 10, 12]. Recently, we reported that
exposure of bone marrow stem cells to the G9a histone methyltransferase (HMTase) inhibitor BIX01294 can enhance
their cardiac competency [13, 14]. Bone marrow mesenchymal stem cells (MSCs) treated with BIX01294 showed an
induced expression of Mesp1 and brachyury [13, 14], which
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are markers associated with precardiac progenitors in the
early embryo [15–17]. Moreover, BIX01294 treatment subsequently allowed MSCs to undergo myocardial diﬀerentiation in response to Wnt11 [13, 14], which is a primary
extracellular factor that initiates cardiogenesis during early
development [18–21].
Wnt proteins are generally classiﬁed into two groups,
based on the primary signal transduction pathways that they
stimulate [22–26]. In the embryo, Wnt11 promotes cardiogenesis via noncanonical Wnt pathways [18–21, 23],
which are distinct from canonical Wnt pathways that signal
via β-catenin [22, 26]. Canonical Wnts, such as Wnt3a,
stimulate cellular responses by preventing the degradation
of β-catenin, which allows this latter protein to accumulate and transduce signal. Although canonical Wnt signaling plays a positive role in advancing the development of
the heart after it initially takes form during embryogenesis,
inhibition of β-catenin-mediated signaling is believed to be
a key event initiating cardiac speciﬁcation in the early
embryo [21, 23, 27, 28].
The eﬀect of BIX01294 on bone marrow cells was discovered as part of a large screen of pharmacological reagents for
their eﬀect on the cardiopotency of bone marrow stem cells
[13, 14]. Drugs used in this analysis were selected based on
their previously described utility for assisting the production
and/or maintenance of pluripotent stem cells in combination
with other treatments [29–32]. In our screening assays, these
drugs were tested whether they were capable of broadening
the cell phenotypic potential on bone marrow stem cells,
without making the cells pluripotent [13, 14]. Of the drugs
we analyzed, only BIX01294 displayed a capability to boost
the cardiac competency of bone marrow cells. However, since
the other drugs we screened had a reported eﬃcacy in helping generate pluripotent cells, but only as part of a compound
treatment, we examined whether any of these reagents were
capable of further enhancing the eﬀect of BIX01294 in broadening the diﬀerentiation potential of bone marrow cells.
Here, we report that the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) synergizes with BIX01294 in inducing cardiac gene expression from MSCs. Moreover, analysis
of the mechanisms that underlie the acquisition of cardiac
competency by MSCs demonstrates that G9a HMTase inhibition displays synergy with HDAC suppression in modifying histone H3 and with Wnt11 in blocking β-catenin
accumulation within stem cell cultures.

2. Material and Methods
2.1. Isolation and Culture of Bone Marrow MSCs. The Institutional Animal Care and Use Committee at New York Medical College approved all animal protocols of this study.
Bone marrow was harvested from 8–12 wk C57BL/6 mice,
as described [33, 34]. MSCs were obtained from bone marrow using standard procedures [35, 36]. Dissociated bone
marrow cells were resuspended at 106 cells/ml in Iscove’s
Modiﬁed Dulbecco’s Medium (IMDM)/20% FBS and plated
onto tissue culture plastic, with nonadherent cells removed
after 4 hrs. The remaining adherent cells were cultured for 2
weeks and then split when still subconﬂuent. Cultures were
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harvested at the second passage, just prior to reaching conﬂuency, for use in experimentation.
Treatments of MSCs were initiated by serum starvation overnight in IMDM and then culturing in fresh
10% FBS/IMDM in the absence or presence of various doses
of BIX01294, 1,5-naphthyridine pyrazole derivative-19
(Npy19; RepSox), CHIR99021, IWP4 (Stemgent), 5azacytidine (Sigma), 3-bromo-7-nitroindazole, and/or trichostatin A (Cayman Chemical). Two days later, cells were
either harvested for RNA or cultured for an additional seven
days in fresh 10% FBS/IMDM medium, plus or minus
Wnt11, or Wnt3a (250 ng/ml; PeproTech) as previously
described [13, 14].
2.2. RNA Isolation and PCR Ampliﬁcation. Quick-RNA
MiniPrep kits (Zymo Research) were used to obtain total
RNA, which was subsequently reverse-transcribed with
Moloney murine leukemia virus reverse transcriptase (Promega). Comparative levels of gene expression were determined by quantitative real-time PCR (qPCR) analysis using
the SYBR Green qPCR Master Mix kit (http://bimake.com).
Levels of phenotype-speciﬁc gene expression were normalized to the expression of the housekeeping gene GAPDH
and calculated by the ΔΔCt method, as described [14, 37].
2.3. Immunoﬂuorescence and Immunoblotting. Immunoﬂuorescent labeling of cultured cells was performed as previously
described [38, 39]. Mouse anti-β-catenin monoclonal antibody (BD Transduction Laboratories) was applied to MSC
cultures following processing with Dent’s ﬁxative (80%
methanol/20% DMSO) and overnight block with 1% BSA/
PBS. Staining with antimuscle α-actinin (EA-53, Sigma)
and titin (9D10, Developmental Studies Hybridoma Bank)
antibodies followed formalin ﬁxation and overnight blocking
with 5% BSA/PBS. DyLight 488 or TRITC-conjugated secondary antibody (Jackson ImmunoResearch) was used to
detect primary antibody labeling of the cultures, with cells
counterstained with 4′,6′-diamidino-2-phenyindole (DAPI;
Life Technologies) to identify nuclei.
For immunoblot analysis, protein was extracted from
MSCs by lysis in RIPA buﬀer (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1% sodium deoxycholate, 0.1% sodium
dodecyl sulfate, and 1% Triton X-100) that contained
Mammalian ProteaseArrest protease inhibitors (G-Biosciences). Polyacrylamide gel electrophoresis was used to separate total protein, which was transferred to polyvinyl
diﬂuoride membrane, and incubated with rabbit antibodies
speciﬁc to dimethylated H3K9, dimethylated H3K27, acetylated H3K9, acetylated H3K27 (Cell Signaling Technology),
or total histone H3 (Millipore). Antibody labeling was
detected using alkaline phosphatase-coupled anti-rabbit IgG
antibody (Promega) and Luminata Forte Western HRP substrate (EMD Millipore).
2.4. Tabulating Immunolabeled Positive Cells. The percentage
of MSCs that expressed muscle α-actinin or β-catenin protein under various culture conditions was determined from
imaging immunoﬂuorescent labeled cell cultures. MSCs were
plated onto 8-well chamber slides (Nunc) and sequentially
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Figure 1: TSA synergistically enhances stimulation of Mesp1 expression by BIX01294. MSCs were incubated with various compounds plus or
minus BIX01294 over a broad range of concentrations, with RNA harvested 2 days later and analyzed for Mesp1 expression by qPCR. The
chart presents summarized results using optimized doses of inhibitors speciﬁc for G9a HMTase (BIX01294), DNA methylation (5azacytidine (5aza)), nitric oxide synthase (3-bromo-7-nitroindazole (BNI)), GSK3β (CHIR99021 (CHIR)), Wnt (IWP4), TGFβ (1,5naphthyridine pyrazole derivative-19 (Npy19)), and histone deacetylase (trichostatin A (TSA)). The numbers of biological repeats
represented in the graphed data are as follows: control and BIX01294 (n = 31) and BIX01294+TSA (n = 18), with remaining groups having
n values ranging from 3 to 5. BIX01294 was the only reagent by itself that was able to induce Mesp1 expression, with >83-fold increase
over control levels (∗∗ p < 0 005). None of the other drugs were able to increase Mesp1 expression. However, of these latter drugs, only
TSA when combined with BIX01294 produced a signiﬁcant enhancement of Mesp1-expression over the levels obtained from the
BIX01294 only treated cultures (∗∗ p < 0 005). Note that the relative levels of Mesp1 gene expression are normalized to levels obtained
from BIX01294-treated MSC cultures.

cultured in the absence or presence of BIX01294±TSA for 2
days and Wnt for 2 or 7 days, prior to immunoﬂuorescent
staining against α-actinin or β-catenin and then counterstaining with DAPI. Digitized images were obtained with a
Zeiss LSM 710 confocal microscope using a 10x objective
from three distinct ﬁelds within the center, upper-right, and
lower-left areas of each well. These images were then
imported into ImageJ software (http://imagej.net/), with total
cell numbers tabulated from DAPI stained images using the
automated particle analysis function and immunolabeled
cells manually counted using the Cell Counter plugin (Kurt
De Vos, University of Sheﬃeld; kurt.devos@iop.kcl.ac.uk).
Each experimental condition was repeated ≥three times and
the percentage of cells identiﬁed by DAPI labeling that
stained positive for either of the two proteins being compiled
and statistically analyzed.
2.5. Statistics. Statistical analysis was determined with
ANOVA followed by the Tukey-Kramer test for comparisons
between multiple groups and with the unpaired Student’s
t-test for evaluating diﬀerences between individual treatments and speciﬁc control groups. Statistical signiﬁcance
was computed with the InStat statistical program (GraphPad
Software) and deﬁned as p ≤ 0 05, with error bars corresponding to the standard error of the mean.
2.6. Cocultures of MSCs with Neonatal Rat Cardiomyocytes.
Neonatal rat cardiomyocytes were used for coculture with
mouse MSCs. Myocytes were obtained from hearts of oneday-old Wistar rats (Taconic Biosciences, Hudson, NY,

USA), as previously described [39]. After their isolation, rat
cardiomyocytes were allowed to attach for at least 2 days
before their use for MSC coculture experimentation. Mouse
MSCs were initially pretreated in the presence or absence of
8 μM BIX01294±50 nM TSA for 48 hrs, prior to their labeling
with 20 μM carboxyﬂuorescein succinimidyl ester (CFSE)
vital dye (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
for 1 hour at 37°C. After extensive washing with PBS,
CFSE-labeled mouse MSCs were plated onto beating rat cardiomyocytes at a ratio of 1 : 10. Cocultures were provided
with fresh 2% FBS/IMDM medium on alternate days and
incubated for two weeks before immunoﬂuorescent staining.
For cocultures, red ﬂuorescent TRITC-labeled secondary
antibody was used in conjunction with the green ﬂuorescent
marker CFSE. However, to avoid confusion with the ﬂuorescence obtained from the MSC only cultures, Adobe Photoshop was used to switch the color channels for cocultures,
with the immunolabeled protein appearing green, while
dye-marked cells are shown as red ﬂuorescence.

3. Results
3.1. TSA Synergistically Enhances BIX01294-Mediated
Responses of Bone Marrow Cells. In previous reports
[13, 14], we described a molecular screen where bone marrow stem cells were exposed to a variety of small molecule
inhibitors that had shown utility in assisting the production
of induced pluripotent stem cells (iPSCs). When these iPSC
helper molecules were tested for their ability to broaden the
potential of bone marrow stem cells, the only one that
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Figure 2: Synergistic enhancement of precardiac gene expression by bone marrow MSCs in response to coaddition of TSA with BIX01294. (a)
MSCs were incubated for 48 hrs with various doses of BIX01294 in absence or presence of 50 nM TSA, prior to harvesting RNA and
measuring Mesp1 expression by qPCR. On the left side of the chart, the y-axis is normalized to Mesp1 levels obtained from MSC cultures
treated with 8 μM BIX01294. The right side y-axis is scaled to the relative increase in Mesp1 expression resulting from the TSA coaddition
to a given concentration of BIX01294. For this series of experiments, BIX01294 generated an ~160-fold increase in Mesp1 expression as
compared to control levels, with TSA coaddition enhancing further the Mesp1 response an additional 5.6-fold. The numbers of biological
repeats represented in the graphed data are as follows: 2 μM BIX01294 and 2 μM BIX01294+TSA (n = 12), with remaining groups having
n values = 14. (b) RNA was assayed for brachyury expression by qPCR, following its isolation from MSC cultures incubated for 48 hrs in
the absence or presence of 8 μM BIX01294 and/or 50 nM TSA. The coaddition of TSA synergistically enhanced BIX01294-stimulation of
brachyury expression 7.2-fold (n = 14; ∗ p < 0 05; ∗∗ p < 0 01).

appreciably upregulated precardiac markers and allowed the
cells to respond to cardiogenic signals was the G9a HMTase
inhibitor BIX01294. As we reported, maximum induction
of the precardiac markers Mesp1 and brachyury was
obtained in cultures treated for 48 hrs with 8 μM BIX01294.
In the present study, we examined if we could increase cardiac gene expression further by employing a secondary
screen to identify molecules that could act synergistically
with BIX01294 for their eﬀect on bone marrow stem cells.
For these experiments, we examined iPSC helper molecules
that were unable to promote precardiac gene expression in
the initial screen, for their ability to enhance the BIX01294
eﬀect on bone marrow MSCs. Therefore, MSCs were treated
with or without 8 μM BIX01294 plus/minus various iPSC

helper molecules over a range of concentrations. After
48 hrs, cultures were assayed for induction of the Mesp1
gene, whose expression is regarded as a marker of the precardiac phenotype in the embryo [15, 17]. These new experiments conﬁrmed that none of the iPSC helper molecules,
save BIX01294, induced Mesp1 expression (Figure 1). More
importantly, none of the other molecules further increased
the level of Mesp1 gene expression induced by BIX01294,
except the histone deacetylase (HDAC) inhibitor trichostatin
A (TSA). Depending on the dosage of these two molecules,
TSA was able to enhance the Mesp1 response of MSCs to
BIX01294 as much as 5.6-fold (Figures 1 and 2(a)). Overall,
the highest levels of Mesp1 expression were generated from
MSCs exposed to the combined treatment of 8 μM

% mRNA levels relative to BIX/WNT11-treated cultures
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Figure 3: TSA coaddition with BIX01294 promotes greater responsiveness to the cardiogenic stimulating factor Wnt11. MSCs were cultured
in the absence or presence of 8 μM BIX01294 plus or minus either 50 nM TSA or 1 μM Npy19 for 48 hrs, prior to seven-day culture in fresh
media with or without Wnt11. (a)–(c) Real-time qPCR analysis of RNA harvested from the cultures indicates that the primary cardiac
transcription factors Nkx2.5, GATA4, and myocardin were signiﬁcantly upregulated in MSCs in response to Wnt11, but only when
pretreated with BIX01294. When TSA (but not Npy19) was combined with BIX01294 during the initial 48 hr incubation period, a
signiﬁcant enhancement was observed for Nkx2.5 (n = 11), GATA4 (n = 11), and myocardin (n = 8) of 4.3-, 2.6-, and 5.6-fold, respectively.
Statistical signiﬁcance is shown for comparative levels of Nkx2.5, GATA4, or myocardin expression displayed by Wnt11 stimulated
cultures pretreated with either TSA plus BIX01294 or BIX01294, and nonpretreatment controls (∗ p < 0 05; ∗∗ p < 0 01). (d) Identiﬁcation
of individual sarcomeric α-actinin positive cells (arrows) by immunoﬂuorescent staining indicated that cardiac protein expression within
the MSC cultures was in accordance to the gene expression patterns, as shown in this panel for cultures treated sequentially with TSA plus
BIX01294 followed by Wnt11. Scale bar = 25 μm. (e) Tabulation of α-actinin positive cells within these cultures demonstrated that
BIX01294 or BIX01294+TSA pretreatments signiﬁcantly increased the number of cardiac protein expressing cells as compared to
nontreated or Wnt11 only conditions. Statistical signiﬁcance is indicated by ∗ p < 0 05; ∗∗ p < 0 01; ∗∗∗ p < 0 001.

BIX01294 plus 50 nM TSA for 48 hrs (Figure 2(a)). Similar
results were obtained for brachyury gene expression, as
TSA was the only molecule tested that demonstrated synergy
with BIX01294, with the two drugs generating levels of brachyury expression that were on average 7.2-fold higher than
elicited with BIX01294 alone (Figure 2(b)).
3.2. BIX01294 and TSA Cooperatively Promote Cardiac
Gene Expression by MSCs. The above results indicated that
TSA synergistically enhanced the induced expression by
BIX01294 of key transcription factors characteristic of
embryonic precardiac progenitors (Figures 1 and 2). Subsequent experimentation demonstrated that TSA also

displayed synergy with BIX01294 in allowing MSCs to
respond to cardiac stimuli and undergo myocardiogenic
diﬀerentiation (Figure 3). For these latter experiments,
MSCs were cultured in the absence or presence of 8 μM
BIX01294±TSA for 48 hrs, prior to subsequent incubation
with the cardiogenic stimulating factor Wnt11. After 7 days
of culture with Wnt11, RNA was harvested from the cells
and analyzed for cardiac gene expression by real-time qPCR.
MSCs collected from cultures that were not exposed to
BIX01294 displayed only minimal expression of cardiac
genes, regardless of whether or not they were subsequently
treated with Wnt11. However, preincubation of MSCs with
BIX01294 allowed for the induced expression of the cardiac
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Figure 4: Expression of sarcomeric α-actinin by MSCs cultured under various conditions. MSCs were immunostained for α-actinin (green)
and DAPI counterstained (blue), after incubation in the presence or absence of BIX01294 and/or TSA for 2 days and Wnt treatments for 7
days. MSCs treated with Wnt11 following exposure to (a) BIX01294 or (b), (c) BIX01294+TSA exhibited clusters of α-actinin-positive cells.
(c) A higher magniﬁcation view of the boxed area in the previous panel indicates that the high intensity α-actinin staining was not yet
exhibited in a striated pattern. In contrast, α-actinin staining was not observed either if the cultures were (d) not pretreated with
BIX01294±TSA or if pretreatment with BIX01294 and TSA was followed by either (e) the absence of Wnt11 or (f) treatment with Wnt3a
instead of Wnt11. Scale bar = 25 μm.

transcription factors Nkx2.5, GATA4, and myocardin in
response to Wnt11 (Figures 3(a), 3(b), and 3(c)). No
enhancement over this BIX01294-mediated response was
observed when the cultures were supplemented during the
48 hr pretreatment phase with other iPSC helper molecules
(e.g., the TGFβ inhibitor Npy19)—except when TSA was
supplied. Again, BIX01294 and TSA displayed synergy, as
this combined pretreatment allowed Wnt11 to generate
levels of Nkx2.5, GATA4, and myocardin that were 4.3-,
2.6-, and 5.6-fold greater than those produced by cultures
that were pretreated with BIX01294 alone (Figures 3(a),
3(b), and 3(c)).
We next examined the extent that BIX01294 and TSA
enhanced the prevalence of cardiac phenotypes within the
MSC-derived cultures. For these experiments, MSCs were
plated at densities that allowed individual cardiac protein
positive cells to be deﬁnitively identiﬁed within the cultures.
MSCs were sequentially incubated in the absence or presence
of BIX01294±TSA for 2 days and Wnt11 for 7 days, prior to
immunoﬂuorescent staining for sarcomeric α-actinin

(Figure 3(d)). Tabulation of immunoﬂuorescent-labeled cells
(Figure 3(e)) indicated that Wnt11 in combination with
BIX01294 or BIX01294+TSA pretreatments exhibited α-actinin staining in 5.46 and 5.57% of cells, respectively, within
the cultures as compared to cells cultured with Wnt11 only
(1.87%) or nontreated conditions (0.32%). MSCs plated at
higher densities generated clusters of α-actinin-positive cells
in response to Wnt11 when pre-exposed to BIX01294
(Figure 4(a)) or BIX01294+TSA (Figures 4(b) and 4(c)).
High-resolution views of these α-actinin-positive cells within
these cultures indicated that this sarcomeric protein was
exhibited in a nonstriated pattern (Figure 4(c)). In contrast,
α-actinin-positive cell clusters were not observed if the cultures were either not pretreated with BIX01294±TSA
(Figure 4(d)), or if Wnt11 was absent (Figure 4(e)) or
replaced with the noncardiogenic growth factor Wnt3a
(Figure 4(f)) following pretreatment with BIX01294±TSA.
Further indications that MSCs could be converted to cardiac
phenotypes was provided by their expression of the sarcomeric protein titin when stimulated with Wnt11 after
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Figure 5: Cardiac diﬀerentiation of MSCs following treatment with BIX01294±TSA. (a), (b) MSCs were immunostained for titin (green) and
DAPI counterstained (blue), after 7 day incubation with Wnt11, following pretreatment with (a) BIX01294 or (b) BIX01294+TSA. (c)–(f)
Coculture of CFSE vital dye-labeled MSCs (red) with neonatal rat cardiomyocytes that were immunostained for α-actinin (green) and
DAPI counterstained (blue). (c) MSCs that were nontreated prior to coincubation with rat myocytes did not display cardiac phenotypes,
as indicated by cells that exhibited only the red vital dye (arrowheads). (d)–(f) In contrast, MSCs pretreated with BIX01294 label showed
evidence of cardiac diﬀerentiation when in proximity to the rat myocytes. (d) While the majority of MSCs in these later cultures remained
nondiﬀerentiated, as indicated by the sole display of the red vital dye (arrowheads), individual BIX01294-treated MSCs were observed that
exhibited dual red and green ﬂuorescence (arrow). (e), (f) Higher-magniﬁcation view of this coculture shown in the successive panels for
both the vital dye ﬂuorescence and actinin immunostaining or vital dye-label only indicates that the red and green colabeled MSC-derived
cell (arrow) exhibits α-actinin in a striated pattern. Scale bar = 25 μm.

exposure to BIX01294 (Figure 5(a)) or BIX01294+TSA
(Figure 5(b)). Consistent with these results were experimental
data indicating that BIX01294 pretreatment enabled MSCs
to undergo cardiac diﬀerentiation and show evidence of a
striated muscle phenotype when cocultured with primary
neonatal rat cardiomyocytes (Figures 5(c), 5(d), 5(e),
and 5(f)).
3.3. Mechanisms of BIX01294 and TSA Action on Bone
Marrow MSCs. To begin to decipher how BIX01294 and
TSA synergistically upregulated cardiac gene expression, we
looked at the global methylation and acetylation patterns of
histone H3 (Figure 6). Incubation of MSCs in BIX01294
reduced methylation of histone H3 at both lysine 9 (H3K9)
and lysine 27 (H3K27). The coaddition of TSA did not
aﬀect this BIX01294-mediated decrease in methylation at
H3K9 and H3K27, nor did the presence of TSA by itself

reduce histone H3 methylation at either lysine residue
(Figures 6(a) and 6(b)). As expected, acetylation at H3K9
and H3K27 was enhanced by TSA, but not by BIX01294.
When TSA and BIX01294 were added together, the
acetylation at lysine 9 was similar to the levels obtained
when TSA was added alone (Figure 6(c)). Yet, the acetylation
pattern at lysine 27 had a diﬀerent result, as coaddition
of BIX01294 synergistically enhanced the TSA-mediated
acetylation at H3K27 (Figure 6(d)), which is a marker
of active enhancers that are enriched during cardiac
development [40–43].
As a second element in elucidating the regulatory mechanism of BIX01294 and TSA enhancement of MSC cardiac
competency, we investigated how these reagents aﬀected
the intracellular expression of β-catenin, which is a downstream target for Wnt signal transduction. Again, bone marrow MSCs were subjected to a two-part culture protocol with
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Figure 6: Modiﬁcation of histone H3 by BIX01294 and TSA.
Protein was isolated from bone marrow MSCs that were cultured
in the absence or presence of BIX01294 and/or TSA. Following
electrophoretic separation, the protein preparations were blotted
with antibodies that recognized either total or speciﬁcally modiﬁed
histone H3. (a), (b) Immunoblots of total protein demonstrated
that methylation of H3K9 and H3K27 was reduced by G9a
HMTase inhibition by BIX01294. (c) Treatment with the HDAC
inhibitor TSA led to increased acetylation at H3K9. (d) While
culturing MSCs with TSA also enhanced H3K27 acetylation, this
increase was slight. However, the coaddition of BIX01294 to TSA
synergistically stimulated the acetylation of this lysine residue. (e)
Blotting for total histone H3 as control veriﬁed that each cellular
sample consisted of equal amounts of protein.

an initial treatment in the absence or presence of BIX01294
plus or minus TSA for 2 days. Subsequently, these MSC cultures were incubated for two additional days with or without
Wnt11, prior to their ﬁxation and immunoﬂuorescent staining for β-catenin (Figures 7 and 8). Cultures of nontreated
MSCs exhibited large numbers of cells that exhibited
high-intensity β-catenin staining (Figure 7(a)). Prevalence
of β-catenin-positive cells was not overtly diminished by
treatment with BIX01294 (Figure 7(b)). Cultures that were
exposed to Wnt11 without prior exposure to BIX01294,
also exhibited prominent β-catenin staining (Figure 7(c)).
When viewed at higher magniﬁcation (Figures 7(d), 7(e),
and 7(f)), the cells that displayed high β-catenin immunoreactivity appeared to exhibit this protein within the cytoplasm, perinuclear region, and nuclei (Figures 7(e) and
7(f)). However, the presence of the brightly stained βcatenin-positive cells was eliminated when MSCs were
sequentially exposed to BIX01294 and Wnt11 (Figure 8(a)).
In contrast, pretreatment with TSA, prior to Wnt11 exposure, did not cause a reduction in β-catenin immunoreactivity (Figure 8(b)). But when TSA was combined with
BIX01294, subsequent treatment with Wnt11 prevented

the appearance of brightly stained β-catenin-positive cells
(Figure 8(c)). In consideration of the known diﬀerential
properties of Wnt11 and Wnt3a, it was not surprising that
the prevalence of β-catenin-positive MSCs increased when
cultures were treated with Wnt3a without prior exposure
to BIX01294 (Figure 8(d)). What was surprising, however,
was the obvious decrease in β-catenin immunoreactivity
when the cultures were ﬁrst treated with BIX01294 prior
to Wnt3a exposure (Figure 8(e)). This eﬀect of BIX01294
pretreatments in reducing β-catenin expression was veriﬁed
statistically by tallying the numbers of immunoreactive cells
that were present under these various conditions. For
cultures that were not pretreated with BIX01294, 7.5% and
36% of the cells, respectively, exhibited high β-catenin
immunoreactivity in response to Wnt11 or Wnt3a. However,
cultures treated with either Wnt protein saw a drop in the
prevalence of these immunolabeled cells to <1%, when previously exposed to BIX01294. The implications of these ﬁndings in regard to crosstalk between epigenetic and WNT
regulation of stem cell speciﬁcation are discussed below.

4. Discussion
Bone marrow has long attracted the attention of research scientists and clinicians for use in cardiac repair because it provides an accessible and abundant source of stem cells [6–11].
However, the initial hope that bone marrow stem cells would
provide an eﬀective treatment for cardiac disease has yet to
come to fruition. The development of technologies for converting adult somatic cells to iPSCs, which in turn can give
rise to cardiomyocytes, has indicated that noncardiac tissues
may serve as a resource of cells that potentially could be used
for repairing a diseased or damaged heart [44–47]. An obstacle in using iPSCs for stem cell therapy is that pluripotent
cells possess a proliferative and diﬀerentiation potential that
is diﬃcult to control and can lead to tumorigenesis [48, 49].
Even when iPSCs are used to generate nonpluripotent progenitor of diﬀerentiated cells, or if somatic cells are coaxed
to dediﬀerentiate to a pluripotent state and then subsequently
diﬀerentiate in the same dish [44], the presence of contaminating pluripotent cells within the ﬁnal cell preparation
may potentially carry a risk of tumor formation or inappropriate tissue remodeling. An alternative approach for producing cardiopotent stem cells from accessible adult tissues
is to harvest their stem cells and expose them to treatments
that would broaden their diﬀerential potential, but without
making the cells pluripotent [13, 14]. It is this approach that
we have pursued in screening pharmacological reagents,
which had been utilized as components of treatments that
are able to contribute to generating iPSCs [29–32], for their
utility in expanding the diﬀerentiation potential of bone marrow MSCs.
The present study is a continuation of our previous
eﬀorts into developing protocols for converting MSCs to a
cardiac competent phenotype [13, 14]. The hypothesis
underlying this research is based on the shared mesodermal
lineage of bone marrow and heart. Accordingly, if the diﬀerentiation potential of bone marrow MSCs could be broadened, while stopping short of making the cells pluripotent,
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Figure 7: β-catenin expression within MSCs cultures. MSCs were immunostained for β-catenin (green) and nuclear counterstained with
DAPI (blue), following a two-step protocol that involved the culturing of cells (1) for 2 days in the absence or presence of BIX01294 and
then (2) for an additional 2 days with or without Wnt11. (a) MSCs cultured without treatment contained many brightly stained βcatenin-positive cells. (b) Cultures treated with BIX01294 without Wnt11 or (c) with Wnt11 without pretreatment also displayed many
brightly stained β-catenin-positive cells. (d)–(f) Higher magniﬁcation views of nontreated MSCs revealed the pattern of β-catenin
ﬂuorescence within these cells. (e), (f) High resolution of brightly stained β-catenin-positive cells shown in successive panels for β-catenin
immunoreactivity only or both β-catenin and DAPI ﬂuorescence, indicated that β-catenin protein is displayed within the cytoplasm,
perinuclear region (arrow), and nucleus (arrow). Scale bar = 20 μm.

these cells could be converted to cardiocompetent, panmesodermal cells. Our previous investigations have demonstrated
that the G9a HMTase inhibitor BIX01294 will cause these
cells to exhibit the early mesodermal, precardiac markers
Mesp1 and brachyury, without any corresponding enhancement of either endodermal, ectodermal, or pluripotency
markers [13]. Furthermore, we showed that BIX01294 treatments allowed bone marrow cells to express cardiac genes
and proteins in response to the cardiogenic stimulus Wnt11
[13, 14]. Here, we report our results with a secondary screen
that demonstrated that coaddition of the HDAC inhibitor
TSA with BIX01294 increased the expression of Mesp1 and
brachyury, 5.6- and 7.2-fold, respectively, over levels induced
by BIX01294 exposure alone. Additionally, we have shown
that the TSA acted synergistically with BIX01294 to upregulate GATA4, Nkx2.5, and myocardin in response to Wnt11.
Thus, incubation of MSCs with Wnt11, following exposure
to both BIX01294 and TSA, resulted in GATA4, Nkx2.5,
and myocardin expression levels that were 2.6- to 5.6-fold

greater than those of cultures pretreated with BIX01294
only—which was 35- to 45-fold above and beyond the levels
generated from cultures incubated with Wnt11 without any
pretreatment. Moreover, data in this report indicated that
these pharmaceutical reagents, which prevent speciﬁc modiﬁcations of histone H3, signiﬁcantly enhanced the ability of
Wnt11 to promote cardiac protein expression, suggesting
that the MSC cultures gave rise to cells exhibiting an immature cardiac phenotype.
BIX01294 and TSA are small molecule inhibitors of epigenetic modifying enzymes that, respectively, demethylate
and acetylate histone lysine residues [50–54]. The mechanistic importance of these epigenetic changes in inﬂuencing
MSC gene expression and diﬀerentiation potential is indicated by two ﬁndings outlined in this study, which are summarized in Figures 9 and 10. The ﬁrst ﬁnding, which may
explain how the coaddition of TSA boosts BIX01294mediated cardiac gene expression, is that these two molecules
synergistically act to upregulate H3K27 acetylation (Figures 6
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Figure 8: Diﬀerential β-catenin immunoreactivity by MSCs cultured under various conditions. MSCs were ﬂuorescently labeled with βcatenin antibody (green) and DAPI nuclear stain (blue), after culturing cells for 2 days in the absence or presence of BIX01294 and/or
TSA and for an additional 2 days with or without Wnt11 or Wnt3a. (a) MSCs cultured in sequence with BIX01294 and Wnt11 were
deﬁcient in cells that brightly stained for β-catenin. In contrast, (b) cultures treated sequentially with TSA and Wnt11 still displayed
numerous brightly stained β-catenin-positive cells. (c) However, MSCs pretreated with both BIX01294 and TSA, followed by Wnt11
exposure, no longer displayed cells with high-intensity β-catenin immunoreactivity. (d) MSCs treated with Wnt3a showed a marked
increase in β-catenin-positive cells. (e) Yet, this high-intensity β-catenin immunoreactivity disappeared when MSCs were ﬁrst exposed to
BIX01294 prior to treatment with Wnt3a. Scale bar = 50 μm. (f) Tabulation of immunoﬂuorescent cells under these various conditions
veriﬁed that BIX01294 pretreatments decreased the number of brightly stained β-catenin-positive cells that were derived from the
cultures. Statistical signiﬁcance is indicated by ∗∗ p < 0 01.

and 9). The epigenetic repercussions of BIX01294 and TSA
treatments share similarities, as their eﬀect on histone H3
demethylation and acetylation relaxes the structure of chromatin that then promotes gene transcription [55, 56]. Yet,
one of the diﬀerences between BIX01294 and TSA is that
the former is a much more selective inhibitor. BIX01294
has a narrow target range, as its inhibitory activity is speciﬁc
for the related histone methyltransferases G9a and G9arelated protein (GLP) [50, 52, 57]. Both enzymes act on the
same lysine residues of histone H3 and exert their function
in vivo by forming homomeric or heteromeric complexes.
In contrast, TSA is a broad-spectrum inhibitor that aﬀects
all class I, II, and IV HDACs [51, 54, 58]. These latter
enzymes catalyze the deacetylation of lysine residues within
the aminoterminal tail of core histone proteins H2A, H2B,
H3, and H4. In addition, each HDAC protein has multiple
nonhistone targets, which may account for the functional differences among the various HDAC proteins and complicate

the analysis of HDAC involvement in epigenetic regulation.
It is unclear if improved outcomes in promoting a cardiac
phenotype could be obtained if more selective HDAC inhibitors were employed. In that regard, experiments using
MOCPAC or BATCP—which are preferential inhibitors of
class I or II HDACs, respectively [59]—generated results
similar to TSA in enhancing BIX01294 stimulation of precardiac gene expression (not shown). This latter observation is
supportive of the interpretation that the TSA eﬀect on MSC
cultures is due to its inﬂuence on histone modiﬁcation.
Moreover, the synergism between BIX01294 and TSA in both
promoting cardiac gene expression and H3K27 acetylation
correlates with observations in the early embryo that have
shown that acetylated H3K27 is a key marker of cardiomyocyte diﬀerentiation and heart development [40–43].
The second ﬁnding is that BIX01294 pre-exposure acts
synergistically with Wnt11 to downregulate cellular βcatenin levels. Wnts play a multifaceted role during the
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Figure 9: Model for BIX01294 and TSA mediated induction of MSC cardiocompetency. (a) G9a HMTase and HDAC activity in MSCs
maintains precardiac genes in a closed chromatin conﬁguration and thus are transcriptionally silent. BIX01294 treatment inhibits G9a
HMTase methylation of histone H3 lysine residues H3K9 and H3K27 within genes associated with precardiac progenitors, such as Mesp1
and brachyury, thus allowing these genes to be expressed and conferring MSCs with a precardiac cell potential. (b) While inhibition of
HDACs by TSA is not suﬃcient to promote Mesp1 or brachyury expression from bone marrow MSCs, this drug acts synergistically
(asterisk) with BIX01294 in the transcriptional activation of precardiac gene expression and acquisition of a cardiac competent cell
phenotype. We hypothesize that this enhanced precardiac gene expression and cardiocompetency supported by the coaddition of these
two drugs is due to their cooperative enhancement of H3K27 acetylation (asterisks), which is a known epigenetic indicator of cardiac gene
expression in the early embryo.

development of the heart [21, 23, 27, 60, 61]. Wnt11 is a primary stimulus for heart development and whose expression
correlates with a corresponding inhibition of β-catenin signaling in the early mesoderm. After the initial formation of

the primary heart tube, localized and temporal expression
of both canonical and noncanonical Wnts regulate the
remodeling and growth of the heart. A hallmark of canonical
Wnt signal transduction is that it promotes the stability and

12

Stem Cells International
Mesenchymal stem cells

Treatments
Nontreated

Wnt11

2 days

≤7 days

Nontreated

Wnt3a
≤7 days

Negative

BIX01294

Nontreated

Negative

(±TSA)
2 days

≤7 days

2 days

BIX01294

Negative

Wnt3a
≤7 days

Negative

BIX01294

Wnt11

Positive

(±TSA)
2 days

≤7 days

(±TSA)
2 days

훽-catenin-negative
Cardiac-negative

Cardiac gene expression

훽-catenin-positive
Cardiac-negative

훽-catenin-negative
Cardiac-positive

Figure 10: Model of epigenetic and Wnt regulation of cardiogenesis. Results presented in this study indicate that BIX01294 induces a
precardiac phenotype from MSCs and acts cooperatively with Wnt11 in promoting both cardiac diﬀerentiation and inhibiting the
intracellular accumulation of β-catenin. Inhibition of β-catenin accumulation by cells of the early mesoderm has been postulated to be a
key element in the initiation of heart formation. Thus, we hypothesize that the BIX01294 prerequisite for generating cardiac phenotypes
from MSCs is twofold: (1) to promote gene expression that is in accordance with a precardiac phenotype and (2) cooperatively allow
Wnt11 to reduce cellular β-catenin levels, thereby initiating cardiac diﬀerentiation of the treated MSCs.

activity of β-catenin [22–26]. Noncanonical Wnts, such as
Wnt11, are thought to act in opposition to canonical Wnt
signaling, in part by preventing the intercellular accumulation of β-catenin [62–64]. As described in this study, MSC
cultures contained large numbers of brightly stained βcatenin-positive cells. This high-intensity staining for βcatenin persisted in the cultures regardless of whether
BIX01294, TSA, or Wnt11 was present. Consistent with the
current understanding of Wnt signal transduction, the prevalence of brightly stained β-catenin-positive cells increased
further when MSCs cultures were treated with the canonical
Wnt protein Wnt3a. Surprisingly, there was a signiﬁcant
reduction in the number of cells exhibiting high-intensity
β-catenin immunoreactivity when cultures were pretreated
with BIX01294 and then subsequently exposed to Wnts—regardless of whether the stimulus was a canonical (Wnt3a) or
noncanonical (Wnt11) Wnt. Thus, an important signal
transduction outcome of Wnt signaling, in regard to βcatenin stability, appears to be inﬂuenced by the activity of
a key epigenetic modulation enzyme G9a HMTase.
The important outcome of our studies is that pretreatment of MSCs with BIX01294±TSA signiﬁcantly enhanced
cardiac gene and protein expression. Although, there
appeared to be a correspondence between enhanced

cardiogenesis and decreased β-catenin, we are unable presently to determine whether the cells whose β-catenin
expression was downregulated in response to BIX01294
plus Wnt11 are the cells that become cardiac competent
in response to these treatments. However, what we can
say is that the coincidence of downregulated β-catenin
expression and increased cardiocompetence within the cultures (summarized in Figure 10) corresponds to the occurrence of these events during cardiac speciﬁcation in the
early embryo. Yet, the observation that BIX01294 pretreatment caused a reduction in β-catenin immunoreactivity,
but not cardiac protein expression in response to Wnt3a,
suggests that there are additional transduction events initiated by Wnt11 for stimulating cardiac diﬀerentiation.
In summary, we report that coaddition of the HDAC
inhibitor TSA synergistically enhances the ability of the
G9a HMTase inhibitor BIX01294 to promote bone marrow
MSC cardiocompetency. This observation was demonstrated
both by the elevated expression of the embryonic precardiac
markers Mesp1 and brachyury and increases in cardiac
gene and protein expression following subsequent stimulation of the cultures with Wnt11. The cardiac proteinpositive cells described in this report suggest that MSCs
may have diﬀerentiated to an immature myocardial

Stem Cells International
phenotype. Pretreatment with BIX01294 allowed for
Wnt11-mediated reduction of internal β-catenin expression and coaddition of TSA with BIX01294 synergistically
enhanced H3K27 acetylation—which are both known regulatory events associated with cardiac speciﬁcation and
heart formation in the early embryo. Collectively, these
data provide supportive evidence that pharmacological
regulation of stem cell phenotype and diﬀerentiation
potential has utility as an experimental approach for generating cellular tools for the use in cardiac repair.
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